Classification of upper limb spasticity patterns in patients with multiple sclerosis: a pilot observational study

Authors

  • Mirko Filippetti Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy; Canadian Advances in Neuro-Orthopedics for Spasticity Consortium (CANOSC), Kingston, ON, Canada
  • Linde Lugoboni Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy
  • Rita Di Censo Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy; Neurorehabilitation Unit, Department of Neurosciences, University Hospital of Verona, Italy
  • Luca Degli Esposti Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy
  • Salvatore Facciorusso Spasticity and Movement Disorders “ReSTaRt” Unit, Physical Medicine and Rehabilitation Section, Riuniti Hospital, University of Foggia, Foggia, Italy
  • Valentina Varalta Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy; Neurorehabilitation Unit, Department of Neurosciences, University Hospital of Verona, Italy
  • Andrea Santamato Spasticity and Movement Disorders “ReSTaRt” Unit, Physical Medicine and Rehabilitation Section, Riuniti Hospital, University of Foggia, Foggia, Italy
  • Massimiliano Calabrese Neurology Section, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
  • Nicola Smania Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy; Neurorehabilitation Unit, Department of Neurosciences, University Hospital of Verona, Italy
  • Alessandro Picelli Neuromotor and Cognitive Rehabilitation Research Center, Section of Physical and Rehabilitation Medicine, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy; Canadian Advances in Neuro-Orthopedics for Spasticity Consortium (CANOSC), Kingston, ON, Canada; Neurorehabilitation Unit, Department of Neurosciences, University Hospital of Verona, Italy

DOI:

https://doi.org/10.2340/jrm.v56.40548

Keywords:

Botulinum toxins, Multiple sclerosis, Muscle spasticity, Symptom assessment, Upper extremity

Abstract

Objective: The aim of this study was to provide a classification of the upper limb patterns in patients with upper limb spasticity due to multiple sclerosis.

Design: Pilot observational study.

Patients: Twenty-five adult patients with multiple sclerosis suffering from upper limb spasticity who underwent one segmental (i.e., proximal and distal upper limb) botulinum toxin treatment cycle were recruited.

Methods: Patients remained in a sitting position during the evaluation. Upper limb spasticity postures (i.e., postural attitude of a single joint/anatomical region) were evaluated and recorded for the shoulder (adducted/internally rotated), elbow (flexed/extended), forearm (pronated/supinated/neutral), wrist (flexed/extended/neutral) and hand (fingers flexed/thumb in palm).

Results: On the basis of the clinical observations, 6 patterns (i.e., sets of limb postures) of upper limb spasticity have been described according to the postures of the shoulder, elbow, forearm, and wrist.

Conclusion: The patterns of upper limb spasticity in patients with multiple sclerosis described by this pilot study do not completely overlap with those observed in patients with post-stroke spasticity. This further supports the need to consider the features of spasticity related to its aetiology in order to manage patients appropriately.

Downloads

Download data is not yet available.

References

Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol 2014; 72: 132-141.

https://doi.org/10.1159/000360528 DOI: https://doi.org/10.1159/000360528

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.

https://doi.org/10.1056/NEJM200009283431307 DOI: https://doi.org/10.1056/NEJM200009283431307

Cattaneo D, Lamers I, Bertoni R, Feys P, Jonsdottir J. Participation restriction in people with multiple sclerosis: prevalence and correlations with cognitive, walking, balance, and upper limb impairments. Arch Phys Med Rehabil 2017; 98: 1308-1315.

https://doi.org/10.1016/j.apmr.2017.02.015 DOI: https://doi.org/10.1016/j.apmr.2017.02.015

Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015; 5: e00362.

https://doi.org/10.1002/brb3.362 DOI: https://doi.org/10.1002/brb3.362

Newsome SD, Thrower B, Hendin B, Danese S, Patterson J, Chinnapongse R. Symptom burden, management and treatment goals of people with MS spasticity: results from SEEN-MSS, a large-scale, self-reported survey. Mult Scler Relat Disord 2022; 68: 104376.

https://doi.org/10.1016/j.msard.2022.104376 DOI: https://doi.org/10.1016/j.msard.2022.104376

Safarpour Y, Mousavi T, Jabbari B. Botulinum toxin treatment in multiple sclerosis: a review. Curr Treat Options Neurol 2017; 19: 33.

https://doi.org/10.1007/s11940-017-0470-5 DOI: https://doi.org/10.1007/s11940-017-0470-5

Baricich A, Battaglia M, Cuneo D, Cosenza L, Millevolte M, Cosma M, et al. Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: an observational longitudinal study. Front Neurol 2023; 14: 1133390.

https://doi.org/10.3389/fneur.2023.1133390 DOI: https://doi.org/10.3389/fneur.2023.1133390

Dressler D, Altavista MC, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna) 2021; 128: 321-335.

https://doi.org/10.1007/s00702-021-02312-4 DOI: https://doi.org/10.1007/s00702-021-02312-4

Hefter H, Jost WH, Reissig A, Zakine B, Bakheit AM, Wissel J. Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? Int J Rehabil Res 2012; 35: 227-233.

https://doi.org/10.1097/MRR.0b013e328353e3d4 DOI: https://doi.org/10.1097/MRR.0b013e328353e3d4

Picelli A, Vallies G, Chemello E, Castellazzi P, Brugnera A, Gandolfi M, et al. Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis. J Neurol Sci 2017; 380: 132-136.

https://doi.org/10.1016/j.jns.2017.07.026 DOI: https://doi.org/10.1016/j.jns.2017.07.026

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.

https://doi.org/10.1212/WNL.33.11.1444 DOI: https://doi.org/10.1212/WNL.33.11.1444

Nuyens G, De Weerdt W, Ketelaer P, Feys H, De Wolf L, Hantson L, et al. Inter-rater reliability of the Ashworth scale in multiple sclerosis. Clin Rehabil 1994; 8: 286-292.

https://doi.org/10.1177/026921559400800403 DOI: https://doi.org/10.1177/026921559400800403

Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.

https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q DOI: https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q

Kassam F, Lim B, Afroz S, Boissonnault È, Reebye R, Finlayson H, et al. Canadian physicians' use of intramuscular botulinum toxin injections for shoulder spasticity: a national cross-sectional survey. Toxins (Basel) 2023; 15: 58.

https://doi.org/10.3390/toxins15010058 DOI: https://doi.org/10.3390/toxins15010058

Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, et al. OnabotulinumtoxinA injection for poststroke upper-limb spasticity: guidance for early injectors from a Delphi panel process. PM R 2017; 9: 136-148.

https://doi.org/10.1016/j.pmrj.2016.06.016 DOI: https://doi.org/10.1016/j.pmrj.2016.06.016

Tamburin S, Filippetti M, Mantovani E, Smania N, Picelli A. Spasticity following brain and spinal cord injury: assessment and treatment. Curr Opin Neurol 2022; 35: 728-740.

https://doi.org/10.1097/WCO.0000000000001114 DOI: https://doi.org/10.1097/WCO.0000000000001114

Moccia M, Annovazzi P, Buscarinu MC, Calabrese M, Cavalla P, Cordioli C, et al. Harmonization of real-world studies in multiple sclerosis: retrospective analysis from the rirems group. Mult Scler Relat Disord 2020; 45: 102394.

https://doi.org/10.1016/j.msard.2020.102394 DOI: https://doi.org/10.1016/j.msard.2020.102394

Gracies JM, Brashear A. Management of spasticity in stroke and multiple sclerosis. In: Dressler DB, Adib Saberi JC, Altenmüller E, editors. Botulinum toxin therapy. Berlin: Springer; 2012, p. 95-120.

Published

2024-08-25

How to Cite

Filippetti, M., Lugoboni, L., Di Censo, R., Degli Esposti, L., Facciorusso, S., Varalta, V., … Picelli, A. (2024). Classification of upper limb spasticity patterns in patients with multiple sclerosis: a pilot observational study. Journal of Rehabilitation Medicine, 56, jrm40548. https://doi.org/10.2340/jrm.v56.40548

Issue

Section

Short Communication

Categories